ETIDIOH - NEW

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial sponsored by the National Institutes of Health (NIH).  The trial enrollment was stopped in late 2024 when an interim analysis showed that tecovirimat monotherapy was ineffective in the study population. Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. “This study brought us a step forward in better understanding mpox disease and potential treatment strategies,” said Jeanne Marrazzo, M.D., M.P.H., director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID), which sponsored and funded the trial. “We are grateful to the study team and participants for their contributions to groundbreaking research on a disease that we still do not know enough about.” Mpox is caused by a virus that spreads ...

{Excerpt} The zoonotic Orthopoxvirus monkeypox virus includes two main clades (ie, 1 and 2) relevant to human transmission .1 Two major outbreaks of monkeypox virus have occurred since 2022,1–3 and were declared public health emergencies of international concern by WHO in July, 2022, and August, 2024. The first outbreak was caused by a clade 2b strain that quickly spread worldwide, resulting in approximately 100 000 cases and 200 deaths.3 In the second outbreak, the novel clade 1b emerged .4 As of December, 2024, this upsurge has resulted in more than 55 000 reported or suspected cases and approximately 1000 deaths in DR Congo and neighbouring countries, including Burundi, Rwanda, Uganda , and Angola .4 A few imported clade 1b cases have also been reported in the UK, Sweden, Germany, Belgium, France, the USA, Canada , and Thailand .5 Prevention measures include patient isolation and care as well as vaccines. (...) Source: Lancet Infectious Diseases,  https://www.thelancet.com/journ...